IPO WATCH- DBK Pharma’s drawn out relisting will take place in 4Q2017, the company’s chairman Hamdy El Debeky tells Al Borsa on Monday. The company’s relisting on the EGX had been marred by delays after it was initially expected to take place earlier this year. The Egyptian Financial Supervisory Authority had signed off on the company’s fair value assessment of EGP 3.1 per share back in July. We have yet to hear whether the company has settled on advisers for the listing.

Tags: